Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on January 16, 2018. The filing incorporates by reference a press release dated January 16, 2018, regarding clinical trial progress. The registrant is a foreign private issuer based in Kfar Saba, Israel.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational milestones rather than financial performance data.
Material Changes and Operational Updates
- Clinical Trial Expansion: Cellect announced the opening of a second clinical trial site.
- Regulatory Approval: The Data Safety Monitoring Board (DSMB) approved dose escalation for the ongoing trial.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release into the company's Registration Statements on Form S-8 and Form F-3. The text does not provide specific numerical guidance or detailed risk factors beyond the standard incorporation of forward-looking statements.
Key Facts for Investor Verification
- Verify the specific location and patient enrollment status of the newly opened second clinical trial site.
- Confirm the specific dosage levels approved by the DSMB for escalation.
- Review the full text of the press release (Exhibit 99.1) for details on the trial's primary endpoints and timeline.
- Check subsequent filings for financial impact related to the expanded clinical operations.